Caption Management, LLC Allogene Therapeutics, Inc. Transaction History

Caption Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $294,708 - $491,779	59,900 Added 399.33%	74,900 $370,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $84,300 - $166,650	15,000 New	15,000 $94,000
Q3 2021 Nov 12, 2021	SELL	$21.01 - $27.64 $306,746 - $403,544	-14,600 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $342,954 - $522,679	14,600 New	14,600 $380,000
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $45,332 - $62,944	-1,400 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$18.39 - $54.04 $194,934 - $572,824	-10,600 Reduced 88.33%	1,400 $60,000
Q1 2020 May 15, 2020	SELL	$18.22 - $28.25 $117,610 - $182,353	-6,455 Reduced 34.98%	12,000 $234,000
Q4 2019 Feb 13, 2020	BUY	$24.82 - $31.4 $458,053 - $579,487	18,455 New	18,455 $480,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $240M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.